Overview
Monte Rosa Therapeutics is a biotechnology company discovering and developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.
AI+ Ask Fintel’s AI assistant about Monte Rosa Therapeutics, Inc..
Thinking about good questions…
Basic Stats
The share price of Monte Rosa Therapeutics, Inc. as of September 10, 2025 is $4.80 / share. This is a decrease of -4.00% from the prior week. The market cap (or net worth) of Monte Rosa Therapeutics, Inc. as of September 10, 2025 is $296.55 MM.
The Factor Analysis chart (below right) shows a view of Monte Rosa Therapeutics, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 296.55 MM |
| EV | 227.12 MM |
| Shares Out. | 61.72 MM |
| Earnings Date | |
| EPS (TTM) | 0.39 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.94 |
| Short Shares Avail. | 0.95 MM |
| Short Interest | 8.24 MM |
| Short Float | 27.20 % |
| Days to Cover | 29.54 days |
| Risk Free Rate | 4.08 % |
| Price Change (1 yr) | -24.45 % |
| Volatility (1 yr) | 1.18 |
| Beta | 1.22 |
| Sharpe Ratio (1 yr) | -0.24 |
| Sortino Ratio (1 yr) | -0.63 |
| PE Ratio | 12.27 |
| Price/Book | 1.11 |
| Price/TBV | 1.11 |
| Book/Market | 0.90 |
| EBIT/EV | 0.13 |
| EBIT(3yr avg)/EV | -0.33 |
| ROA | 0.07 |
| ROE | 0.11 |
| ROIC | 0.08 |
| CROIC | -0.13 |
| OCROIC | 0.09 |
| Implied Volatility | 73.91 % |
| Put/Call OI Ratio | 0.08 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Monte Rosa Therapeutics, Inc. is $16.61. The forecasts range from a low of $10.10 to a high of $21.00. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Monte Rosa Therapeutics, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-10-13 | UBS | Buy | Initiate | |
| 2022-08-15 | Jefferies | Buy | Initiate | |
| 2022-05-12 | Piper Sandler | Overweight | Maintains | |
| 2022-04-28 | Credit Suisse | Neutral | Initiate | |
| 2022-02-10 | Wells Fargo | Equal-Weight | Initiate | |
| 2021-10-14 | SVB Leerink | Market Perform | Initiate | |
| 2021-07-19 | Piper Sandler | Overweight | Initiate | |
| 2021-07-19 | JP Morgan | Overweight | Initiate | |
| 2021-07-19 | Guggenheim | Buy | Initiate | |
| 2023-01-03 | Wells Fargo | Equal-Weight | Overweight | Upgrade |
| 2023-03-17 | Credit Suisse | Neutral | Maintains | |
| 2023-05-12 | Credit Suisse | Neutral | Neutral | Reiterate |
| 2023-10-19 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-02-15 | Wedbush | Outperform | Initiate | |
| 2023-08-11 | Credit Suisse | Neutral | Neutral | Reiterate |
| 2024-05-22 | Wedbush | Outperform | Outperform | Reiterate |
| 2024-06-28 | Piper Sandler | Overweight | Overweight | Reiterate |
| 2024-09-12 | Wedbush | Outperform | Outperform | Reiterate |
| 2024-12-19 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| 2025-03-21 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2025-03-21 | Wedbush | Outperform | Outperform | Maintains |
| 2024-08-12 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-03-12 | LifeSci Capital | Outperform | Initiate |
